Records containing: Refractory Follicular Lymphoma

This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.

All FDA submission records EMA medicine records ClinicalTrials.gov record updates ClinicalTrials.gov records with results posted

CLINICAL_TRIALS study record update · 2025-04-24
A Phase II Study of Brentuximab Vedotin Plus Bendamustine for Relapsed/Refractory Follicular Lymphoma
CLINICAL_TRIALS study record update · 2025-04-18
Phase II Study of Anti-CD20 Antibody Therapy Plus Pembrolizumab (MK-3475) in Subjects With Relapsed Follicular and Diffuse Large B-Cell Lymphoma
CLINICAL_TRIALS study record update · 2025-04-16
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
CLINICAL_TRIALS study record update · 2024-10-16
Intratumoral Injection of SD-101, an Immunostimulatory CpG, in Combination With Ibrutinib and Local Radiation in Relapsed or Refractory Low-Grade Follicular Lymphoma
CLINICAL_TRIALS study record update · 2024-08-27
A Phase 1/2 Study of Pembrolizumab Plus Pralatrexate for Treatment of Relapsed or Refractory Peripheral T-Cell Lymphomas
Organize your saved records without ads with Plus.
CLINICAL_TRIALS study record update · 2024-05-21
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
CLINICAL_TRIALS study record update · 2024-02-01
A Phase 1 Study of Pembrolizumab Plus Vorinostat for Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma
CLINICAL_TRIALS study record update · 2023-11-29
Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy (REFRACT): A Randomised Phase II Trial of Investigator Choice Standard Therapy Versus Sequential Novel Therapy Experimental Arms
CLINICAL_TRIALS study record update · 2023-10-23
A Phase 2 Randomized Study of Loncastuximab Tesirine Versus Idelalisib in Patients With Relapsed or Refractory Follicular Lymphoma (LOTIS-6)
CLINICAL_TRIALS study record update · 2023-07-07
A Phase 1 Study With a Phase 2 Expansion Cohort of Zandelisib and Tazemetostat in Relapsed or Refractory Follicular Lymphoma
CLINICAL_TRIALS study record update · 2023-05-31
A Phase 1/2 Study of Tazemetostat With Umbralisib and Ublituximab in Patients With Relapsed/Refractory Follicular Lymphoma
CLINICAL_TRIALS study record update · 2023-03-21
A Phase II Study of Anti-PD-1 Antibody (MK-3475) in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Other Low Grade B Cell Non-Hodgkin Lymphoma (NHL)
CLINICAL_TRIALS study record update · 2023-02-16
Immunotherapy With Ex Vivo-Expanded Cord Blood-Derived NK Cells Combined With Rituximab High-Dose Chemotherapy and Autologous Stem Cell Transplant for B-Cell Non-Hodgkin's Lymphoma
CLINICAL_TRIALS study record update · 2023-01-20
Optimizing Post-allogeneic Hematopoietic Cell Transplant Outcomes for Lymphoma Using Ibrutinib
CLINICAL_TRIALS study record update · 2022-09-30
A Phase I Trial of Lenalidomide, Umbralisib and Ublituximab in Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
CLINICAL_TRIALS study record update · 2022-06-07
A Phase Ib/II Study of Duvelisib and Acalabrutinib in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (DUAL Trial)
CLINICAL_TRIALS study record update · 2021-05-05
A Randomized Phase I/II Study of Bortezomib, Rituximab, Dexamethasone and Temsirolimus in Patients With Relapsed Waldenstrom Macroglobulinemia and Relapsed/Refractory Mantle Cell, Follicular, Marginal Zone or Small Lymphocytic Lymphomas (Phase I), and Untreated/Relapsed Waldenstrom Macroglobulinemia (Phase II)
CLINICAL_TRIALS study record update · 2020-01-29
Immunotherapy With Ex Vivo-Expanded Cord Blood-Derived CAR-NK Cells Combined With High-Dose Chemotherapy and Autologous Stem Cell Transplantation for B-Cell Lymphoma
CLINICAL_TRIALS study record update · 2019-10-11
Transplantation of Umbilical Cord Blood in Patients With Hematological Malignancies Using a Reduced-Intensity Preparative Regimen (A Multi-Center Trial Coordinated by the FHCRC)
CLINICAL_TRIALS study record update · 2019-07-30
A Phase I/Ib Study of the PD-1 Antibody Pembrolizumab in Combination With Ibrutinib in Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL)
CLINICAL_TRIALS study record update · 2019-01-28
A Phase 1 Trial of MLN8237 Plus Romidepsin for Relapsed/Refractory Aggressive B-Cell and T-Cell Lymphomas
CLINICAL_TRIALS study record update · 2018-04-26
Phase 2 Trial of Single-Agent Ibrutinib (PCI-32765) in Relapsed or Refractory Follicular Lymphoma